Unknown

Dataset Information

0

Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.


ABSTRACT: Circulating levels of soluble forms of urokinase-type plasminogen activator receptor (suPAR) are generally elevated in sera from children and adults with FSGS compared with levels in healthy persons or those with other types of kidney disease. In mice lacking the gene encoding uPAR, forced increases in suPAR concentration result in FSGS-like glomerular lesions and proteinuria. However, whether overexpression of suPAR, per se, contributes to the pathogenesis of FSGS in humans remains controversial. We conducted an independent set of animal experiments in which two different and well characterized forms of recombinant suPAR produced by eukaryotic cells were administered over the short or long term to wild-type (WT) mice. In accordance with the previous study, the delivered suPARs are deposited in the glomeruli. However, such deposition of either form of suPAR in the kidney did not result in increased glomerular proteinuria or altered podocyte architecture. Our findings suggest that glomerular deposits of suPAR caused by elevated plasma levels are not sufficient to engender albuminuria.

SUBMITTER: Cathelin D 

PROVIDER: S-EPMC4116049 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2011-01-01 | S-EPMC4089394 | BioStudies
2015-01-01 | S-EPMC4585377 | BioStudies
2019-01-01 | S-EPMC6760112 | BioStudies
2019-01-01 | S-EPMC6486353 | BioStudies
2017-01-01 | S-EPMC5405698 | BioStudies
2017-01-01 | S-EPMC5682769 | BioStudies
2018-01-01 | S-EPMC6004767 | BioStudies
2020-01-01 | S-EPMC7065830 | BioStudies
2001-01-01 | S-EPMC1222101 | BioStudies
2017-01-01 | S-EPMC5494859 | BioStudies